S Requena1, A B Lozano2, E Caballero3, F García4, M C Nieto5, R Téllez6, J M Fernández2, M Trigo7, I Rodríguez-Avial8, L Martín-Carbonero9, P Miralles10, V Soriano9,11, C de Mendoza1,12. 1. Puerta de Hierro University Hospital and Research Institute, Madrid, Spain. 2. Hospital de Poniente, Almeria, Spain. 3. Hospital Vall d'Hebró, Barcelona, Spain. 4. Hospital Universitario San Cecilio, Instituto de Investigación Ibs, Granada, Spain. 5. Hospital de Basurto, Bilbao, Spain. 6. Fundación Jiménez-Díaz, Madrid, Spain. 7. Complejo Hospitalario, Pontevedra, Spain. 8. Hospital Clínico San Carlos, Madrid, Spain. 9. Hospital Universitario La Paz, Madrid, Spain. 10. Hospital Universitario Gregorio Marañón, Madrid, Spain. 11. UNIR Health Sciences School, Madrid, Spain. 12. Universidad San Pablo CEU, Madrid, Spain.
Abstract
BACKGROUND: HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. METHODS: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. RESULTS: From a total of 354 HIV-2-infected patients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). CONCLUSIONS: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
BACKGROUND:HIV-2 is a neglected virus despite estimates of 1-2 million people being infected worldwide. The virus is naturally resistant to some antiretrovirals used to treat HIV-1 and therapeutic options are limited for patients with HIV-2. METHODS: In this retrospective observational study, we analysed all HIV-2-infected individuals treated with integrase strand transfer inhibitors (INSTIs) recorded in the Spanish HIV-2 cohort. Demographics, treatment modalities, laboratory values, quantitative HIV-2 RNA and CD4 counts as well as drug resistance were analysed. RESULTS: From a total of 354 HIV-2-infectedpatients recruited by the Spanish HIV-2 cohort as of December 2017, INSTIs had been given to 44, in 18 as first-line therapy and in 26 after failing other antiretroviral regimens. After a median follow-up of 13 months of INSTI-based therapy, undetectable viraemia for HIV-2 was achieved in 89% of treatment-naive and in 65.4% of treatment-experienced patients. In parallel, CD4 gains were 82 and 126 cells/mm3, respectively. Treatment failure occurred in 15 patients, 2 being treatment-naive and 13 treatment-experienced. INSTI resistance changes were recognized in 12 patients: N155H (5), Q148H/R (3), Y143C/G (3) and R263K (1). CONCLUSIONS: Combinations based on INSTIs are effective and safe treatment options for HIV-2-infected individuals. However, resistance mutations to INSTIs are selected frequently in failing patients, reducing the already limited treatment options.
Authors: Robert A Smith; Dana N Raugi; Vincent H Wu; Christopher G Zavala; Jennifer Song; Khardiata Mbaye Diallo; Moussa Seydi; Geoffrey S Gottlieb Journal: Antimicrob Agents Chemother Date: 2019-04-25 Impact factor: 5.191
Authors: Robert A Smith; Vincent H Wu; Jennifer Song; Dana N Raugi; Khardiata Diallo Mbaye; Moussa Seydi; Geoffrey S Gottlieb Journal: J Infect Dis Date: 2022-08-26 Impact factor: 7.759
Authors: Philip L Tzou; Diane Descamps; Soo-Yon Rhee; Dana N Raugi; Charlotte Charpentier; Nuno Taveira; Robert A Smith; Vicente Soriano; Carmen de Mendoza; Susan P Holmes; Geoffrey S Gottlieb; Robert W Shafer Journal: J Infect Dis Date: 2020-06-11 Impact factor: 5.226
Authors: Peter A Minchella; Christiane Adjé-Touré; Guoqing Zhang; Andre Tehe; Judith Hedje; Erin R Rottinghaus; Natacha Kohemun; Micheline Aka; Karidia Diallo; G Laissa Ouedraogo; Kevin M De Cock; John N Nkengasong Journal: BMC Infect Dis Date: 2020-03-12 Impact factor: 3.090